PT-141 (Bremelanotide) | Packaging: 10 mg, Primary Goal: Boosting libido, Secondary Goal: Improving mood and self-esteem

New

PT-141 (Bremelanotide) 10mg – natural sexual stimulant

PT-141 stimulates the pleasure centers and libido, without affecting the cardiovascular system. It is used by men and women, often as part of an anti-aging or wellness protocol. It supports confidence and vitality, especially in active athletes and people with a busy schedule.

0 reviews • Write a review

€ 40.00

Ex Tax: € 40.00

Qty

Add to Cart

Buy Now Question?

Add to Wish List

Ask a Question about this Product

Shipping

Secure and safe worldwide delivery! If the product is on stock - average delivery time is 2-3 days in Eastern Europe, 3-7 days in Western Europe and 1-3 weeks world wide!

Improved storage formula

Improved storage formula - increased stability and extended shelf life!

Quality Control & Tests

High-quality product! All peptides branded MyPeptid are produced in 100% laboratory conditions and have purity above 98%. Our products are tested at JINOSHIK, Analiza Białek and other independent, established laboratories with high standards!

Tags: Increasing libido

Product information

Description of PT-141 (Bremelanotide)

Bremelanotide enhances sexual desire and responsiveness to intimate stimuli by affecting the way the brain "switches on" motivation and bodily arousal, without directly dilating blood vessels.

Technical parameters of Bremelanotide:

Agonist activity at melanocortin receptors (MC3R/MC4R) triggers central neuronal signaling cascades linked to sexual motivation and autonomic responses; this positions the molecule as melanocortin receptor agonist with a primary effect on the CNS (Wikipedia: Bremelanotide).

Bremelanotide is a cyclic peptide analogue, functionally derived from α-MSH, which activates MC4R-associated pathways (Gs/adenylate cyclase → cAMP), modulating hypothalamic-limbic networks. The clinical effect is considered centrally mediated rather than a peripheral vasodilatory mechanism. The regulatory framework and approval for a specific indication are described by FDA (prescribing information and review documents), and the clinical publications are indexed in PubMed.

Clinical data (numerical results):

study name	population or experimental model	number of subjects or samples	duration	key observed outcomes
RECONNECT (1 & 2)	premenopausal women with HSDD	~1,200 total (two phase 3 trials)	24 weeks	Δ satisfying sexual events versus placebo: ~+0.3 to +0.4/month; FSFI-Desire: ~+0.3 to +0.4 points; FSDS-DAO: ~−0.3 to −0.4 points (change from baseline)

The data are presented in regulatory summaries/labeling and related publications; beyond those, quantitative results are limited or heterogeneous and require careful interpretation.

In the laboratory setting PT-141 is suitable for modeling MC4R-mediated effects (receptor panels, cAMP assays, neurobiological readouts). Pharmacokinetically, in human use it is administered subcutaneously with Tmax on the order of hours and elimination on the timescale of hours—practical for acute protocols and crossover designs, but requires timing control relative to stimulus/assessment (FDA).

PT-141 (Bremelanotide) from MyPeptid provides a reliable basis for analytical and functional tests, as it is offered with purity >99% (depending on the batch and COA).

Formula: C50H68N14O10

For sale for educational and research purposes only!